Patients with metastatic pancreatic cancer who had already failed at least one round of chemotherapy lived roughly twice as ...

In a 500-patient phase 3 trial, daraxonrasib extends median overall survival to 13.2 vs 6.7 months for chemotherapy in second-line metastatic pancreatic cancer.

At the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made ...

RAS genes constitute the most regularly mutated oncogene family in cancer. Indeed, RAS genes constituted the most regularly mutated oncogenes in the top three causes of cancer deaths in the US in 2016 ...

The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in patients with previously treated RAS-mutant metastatic pancreatic cancer, according to a Phase I/II ...

Football is a game of inches, and that starts with the draft. In a pool full of talented prospects, each team is trying to get the competitive edge and successfully predict future stars and impact ...

This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data drop earlier this year.